

Marco Massari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1649423/publications.pdf>

Version: 2024-02-01

49
papers

4,020
citations

218677

26
h-index

206112

48
g-index

51
all docs

51
docs citations

51
times ranked

7467
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictive factors of clinical outcomes in patients with COVID-19 treated with tocilizumab: A monocentric retrospective analysis. PLoS ONE, 2022, 17, e0262908.	2.5	2
2	Effect of Fluoroquinolone Use in Primary Care on the Development and Gradual Decay of Escherichia coli Resistance to Fluoroquinolones: A Matched Case-Control Study. Antibiotics, 2022, 11, 822.	3.7	5
3	Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia. JAMA Internal Medicine, 2021, 181, 24.	5.1	593
4	Functional reconstitution of HBV-specific CD8 T cells by in vitro polyphenol treatment in chronic hepatitis B. Journal of Hepatology, 2021, 74, 783-793.	3.7	33
5	Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection. PLoS ONE, 2021, 16, e0247275.	2.5	7
6	Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. Rheumatology, 2021, 60, SI25-SI36.	1.9	13
7	The value of computed tomography in assessing the risk of death in COVID-19 patients presenting to the emergency room. European Radiology, 2021, 31, 9164-9175.	4.5	14
8	The impact of chest CT body composition parameters on clinical outcomes in COVID-19 patients. PLoS ONE, 2021, 16, e0251768.	2.5	26
9	Association of Influenza Vaccination and Prognosis in Patients Testing Positive to SARS-CoV-2 Swab Test: A Large-Scale Italian Multi-Database Cohort Study. Vaccines, 2021, 9, 716.	4.4	12
10	Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project. BioDrugs, 2021, 35, 749-764.	4.6	16
11	High-dose glucocorticoids pulse-therapy for beta-coronaviridae pneumonia: a systematic literature review and case-series of Coronavirus disease-2019. Clinical and Experimental Rheumatology, 2021, 39, 1119-1125.	0.8	5
12	Methylprednisolone as rescue therapy after tocilizumab failure in patients with severe COVID-19 pneumonia. Clinical and Experimental Rheumatology, 2021, 39, 1141.	0.8	0
13	Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation. Critical Care, 2020, 24, 589.	5.8	47
14	Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCOVID-19 prospective trial. Journal of Translational Medicine, 2020, 18, 405.	4.4	98
15	Accuracy of CT in a cohort of symptomatic patients with suspected COVID-19 pneumonia during the outbreak peak in Italy. European Radiology, 2020, 30, 6818-6827.	4.5	33
16	Abdominal Visceral Infarction in 3 Patients with COVID-19. Emerging Infectious Diseases, 2020, 26, 1926-1928.	4.3	30
17	TOCOVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol. Contemporary Clinical Trials, 2020, 98, 106165.	1.8	9
18	Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients. Drug Safety, 2020, 43, 1297-1308.	3.2	48

#	ARTICLE	IF	CITATIONS
19	<p><p>Survival of Hospitalized COVID-19 Patients in Northern Italy: A Population-Based Cohort Study by the ITA-COVID-19 Network</p>. Clinical Epidemiology, 2020, Volume 12, 1337-1346.</p>	3.0	42
20	<p>Susceptibility and severity of COVID-19 in patients treated with bDMARDs and tsDMARDs: a population-based study. Annals of the Rheumatic Diseases, 2020, 79, 986.2-988.</p>	0.9	49
21	<p>Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatology, The, 2020, 2, e474-e484.</p>	3.9	772
22	<p>Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. Hepatology International, 2020, 14, 362-372.</p>	4.2	8
23	<p>Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection. Nature Communications, 2020, 11, 604.</p>	12.8	44
24	<p>Risk of cancer in individuals with alcohol and drug use disorders: a registry-based study in Reggio Emilia, Italy. European Journal of Cancer Prevention, 2020, 29, 270-278.</p>	1.3	4
25	<p><p>May 2020: Is It Always COVID-19 No Matter What?</p>. International Medical Case Reports Journal, 2020, Volume 13, 563-567.</p>	0.8	5
26	<p>Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia. Clinical and Experimental Rheumatology, 2020, 38, 1215-1222.</p>	0.8	3
27	<p>The present profile of chronic hepatitis B virus infection highlights future challenges. Digestive and Liver Disease, 2019, 51, 438-442.</p>	0.9	17
28	<p>Forecasting Hepatitis C liver disease burden on real-life data. Does the <i>hidden iceberg</i> matter to reach the elimination goals?. Liver International, 2018, 38, 2190-2198.</p>	3.9	33
29	<p>Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. Nature Medicine, 2017, 23, 327-336.</p>	30.7	251
30	<p>Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. Hepatology, 2017, 66, 1814-1825.</p>	7.3	25
31	<p>Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PLoS ONE, 2017, 12, e0172159.</p>	2.5	42
32	<p>Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. PLoS ONE, 2017, 12, e0185728.</p>	2.5	37
33	<p>Missed treatment in an Italian HBV infected patients cohort: HBV RER. Digestive and Liver Disease, 2016, 48, 1346-1350.</p>	0.9	2
34	<p>Contrast-enhanced ultrasound appearance of primary epiploic appendagitis. Journal of Ultrasound, 2014, 17, 75-76.</p>	1.3	10
35	<p>Risk of Guillain-Barré syndrome after 2010-2011 influenza vaccination. European Journal of Epidemiology, 2013, 28, 433-444.</p>	5.7	41
36	<p>Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. Journal of Hepatology, 2013, 59, 221-228.</p>	3.7	34

#	ARTICLE	IF	CITATIONS
37	Combined Blockade of Programmed Death-1 and Activation of CD137 Increase Responses of Human Liver T Cells Against HBV, But Not HCV. <i>Gastroenterology</i> , 2012, 143, 1576-1585.e4.	1.3	106
38	Antiviral Intrahepatic T-Cell Responses Can Be Restored by Blocking Programmed Death-1 Pathway in Chronic Hepatitis B. <i>Gastroenterology</i> , 2010, 138, 682-693.e4.	1.3	416
39	Serum Ferritin as a Predictor of Treatment Outcome in Patients With Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2009, 104, 605-616.	0.4	35
40	Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C. <i>Aids</i> , 2007, 21, 2171-2175.	2.2	21
41	Efficacy and risk of rituximab in type II mixed cryoglobulinemia: a significant case report. <i>Digestive and Liver Disease</i> , 2007, 39, S134-S135.	0.9	7
42	PD-1 Expression in Acute Hepatitis C Virus (HCV) Infection Is Associated with HCV-Specific CD8 Exhaustion. <i>Journal of Virology</i> , 2006, 80, 11398-11403.	3.4	521
43	Virus-Specific CD8+ Lymphocytes Share the Same Effector-Memory Phenotype but Exhibit Functional Differences in Acute Hepatitis B and C. <i>Journal of Virology</i> , 2002, 76, 12423-12434.	3.4	168
44	African Sleeping Sickness in Tourists Returning from Tanzania: The First 2 Italian Cases from a Small Outbreak among European Travelers. <i>Clinical Infectious Diseases</i> , 2002, 34, e18-e22.	5.8	37
45	Iron reduction and sustained response to interferon- α therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. <i>American Journal of Gastroenterology</i> , 2002, 97, 1204-1210.	0.4	0
46	Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. <i>American Journal of Gastroenterology</i> , 2002, 97, 1204-1210.	0.4	77
47	Hepatitis C virus (HCV) RNA determination after two weeks of induction interferon treatment is an accurate predictor of nonresponse: comparison of two treatment schedules. <i>Digestive Diseases and Sciences</i> , 2001, 46, 2389-2395.	2.3	7
48	Transmission of Hepatitis C Virus in a Gynecological Surgery Setting. <i>Journal of Clinical Microbiology</i> , 2001, 39, 2860-2863.	3.9	57
49	Conserved hepatitis C virus sequences are highly immunogenic for CD4+ T cells: Implications for vaccine development. <i>Hepatology</i> , 1999, 30, 1088-1098.	7.3	150